Positive top-line results were reported for a phase 3 clinical study investigating APP13007 to treat inflammation and pain after cataract surgery, according to a press release from Formosa Pharmaceuticals and AimMax Therapeutics.
The randomized, double-masked CPN-302 trial, which included 370 participants randomly assigned to receive either APP13007 (clobetasol propionate 0.05%) or placebo after cataract surgery, achieved both primary endpoints of producing rapid and sustained clearance of ocular inflammation and resolving ocular pain after two daily drops for 14 days.
On postoperative day 15,